Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 21 to 30 of 220 total matches.
Three More Immune Checkpoint Inhibitors for Advanced Bladder Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017 (Issue 1535)
% vs 11.4% with
(randomized, open-label, chemotherapy (p=0.001)
phase 3, n=542) DOR: NR
PFS: 2.1 mos ...
The FDA has approved avelumab (Bavencio – EMD
Serono) and durvalumab (Imfinzi – AstraZeneca),
two new immune check point inhibitors, and
pembrolizumab (Keytruda – Merck), a checkpoint
inhibitor that has been available in the US since
2014, for treatment of locally advanced or
metastatic bladder cancer. Nivolumab (Opdivo) and
atezolizumab (Tecentriq) were approved earlier for
this indication.
Autologous Bone marrow Transplantation For Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • May 03, 1991 (Issue 843)
chemotherapy with or without total body radiation, and reinfusing the bone marrow intravenously — is being ...
The prognosis in breast cancer is generally poor for women with unresectable, locally advanced disease (inflammatory cancer or more than 10 positive lymph nodes) and for those with metastases. Autologous bone marrow transplantation - removing bone marrow from multiple sites under general anesthesia, giving high-dose chemotherapy with or without total body radiation, and reinfusing the bone marrow intravenously - is being tried in some of these patients.
Cemiplimab (Libtayo) for NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
chemotherapy than with
chemotherapy alone (21.9 vs 13.0 months). Median
progression-free survival was 8.2 ...
The FDA has approved cemiplimab-rwlc (Libtayo –
Regeneron), an immune checkpoint inhibitor, for use in
combination with platinum-based chemotherapy for
first-line treatment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) in adults with no
epidermal growth factor receptor (EGFR), anaplastic
lymphoma kinase (ALK), or ROS1 aberrations and
who are not candidates for surgical resection or
chemoradiation. The drug was previously approved
for first-line treatment of NSCLC in patients whose
tumors have high PD-L1 expression and no genomic
tumor aberrations....
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e67-8 doi:10.58347/tml.2023.1674e | Show Introduction Hide Introduction
Zolbetuximab (Vyloy) for Gastric and Gastroesophageal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024 (Issue 1717)
or GEJ adenocarcinoma, addition of zolbetuximab to
standard chemotherapy extended progression-free ...
Zolbetuximab-clzb (Vyloy – Astellas), a claudin
18.2 (CLDN18.2)-directed cytolytic antibody, has
been approved by the FDA for use in combination
with fluoropyrimidine- and platinum-containing
chemotherapy for first-line treatment of locally
advanced unresectable or metastatic human epidermal
growth factor receptor 2 (HER2)-negative gastric or
gastroesophageal junction (GEJ) adenocarcinoma in
patients who have CLDN18.2-positive tumors. It is the
first monoclonal antibody to be approved in the US
that selectively targets CLDN18.2.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):e204-5 doi:10.58347/tml.2024.1717g | Show Introduction Hide Introduction
Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017 (Issue 1515)
(NSCLC) that have progressed during or following
platinum-based chemotherapy. Atezolizumab is the
first ...
The FDA has approved the immune checkpoint
inhibitor atezolizumab (Tecentriq – Genentech) for
treatment of locally advanced or metastatic urothelial
carcinoma and metastatic non-small cell lung cancer
(NSCLC) that have progressed during or following
platinum-based chemotherapy. Atezolizumab is the
first programmed death-ligand 1 (PD-L1) blocking
antibody to become available in the US. Two other
immune checkpoint inhibitors, the programmed death
receptor-1 (PD-1) inhibitors nivolumab (Opdivo) and
pembrolizumab (Keytruda), are also approved for
treatment of metastatic NSCLC, and...
Capecitabine and Trastuzumab for Metastatic Breast Cancer
The Medical Letter on Drugs and Therapeutics • Nov 06, 1998 (Issue 1039)
using trastuzumab alone in patients refractory
to chemotherapy, or with paclitaxel (Taxol) for first ...
Trastuzumab (Herceptin - Genentech), a recombinant 'humanized' monoclonal antibody (rhuMAb) that binds to a protein encoded by the oncogene HER2, and capecitabine (ka pe site' a been; Xeloda - Roche), an oral pro-drug for 5-fluorouracil, have been approved by the FDA for treatment of metastatic breast cancer.
Gemtuzumab for Relapsed Acute Myeloid Leukemia
The Medical Letter on Drugs and Therapeutics • Jul 24, 2000 (Issue 1083)
years old
and may not be able to tolerate cytotoxic chemotherapy.
TREATMENT OF AML — Conventional ...
Gemtuzumab ozogamicin, a monoclonal antibody bound to a cytotoxic antibiotic, has been approved by the FDA for treatment of patients with CD33-positive acute myeloid leukemia (AML) in first relapse who are more than 60 years old and may not be able to tolerate cytotoxic chemotherapy
Toripalimab (Loqtorzi) for Nasopharyngeal Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment ...
Toripalimab-tpzi (Loqtorzi – Coherus Biosciences),
a programmed death receptor-1 (PD-1)-blocking
antibody, has been approved by the FDA for use
in combination with cisplatin and gemcitabine for
first-line treatment of recurrent locally advanced or
metastatic nasopharyngeal carcinoma and for use as
monotherapy for treatment of recurrent unresectable
or metastatic nasopharyngeal carcinoma in adults
with disease progression on or after platinum-based
chemotherapy. It is the first immune checkpoint
inhibitor to be approved in the US for treatment of
nasopharyngeal carcinoma.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):e16-7 doi:10.58347/tml.2024.1694e | Show Introduction Hide Introduction
Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
who received
prior endocrine-based therapy and chemotherapy for
unresectable or metastatic disease ...
The FDA has approved datopotamab deruxtecan
(Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast
cell-surface antigen-2 (Trop-2)-directed antibody
and topoisomerase inhibitor conjugate, for treatment
of adults with unresectable or metastatic hormone
receptor (HR)-positive, human epidermal growth factor
receptor 2 (HER2)-negative breast cancer who received
prior endocrine-based therapy and chemotherapy for
unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2 doi:10.58347/tml.2025.1723e | Show Introduction Hide Introduction
Ramucirumab (Cyramza) for Gastric and GEJ Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
(GEJ) adenocarcinoma
that has progressed on or after platinum- or
fluoropyrimidine-based chemotherapy ...
Ramucirumab (Cyramza – Lilly), a monoclonal antibody
that inhibits vascular endothelial growth factor
receptor 2 (VEGFR2), has been approved by the FDA for
use as monotherapy or in combination with paclitaxel
for treatment of advanced or metastatic gastric or
gastroesophageal junction (GEJ) adenocarcinoma
that has progressed on or after platinum- or
fluoropyrimidine-based chemotherapy. Ramucirumab
is also approved for use in combination with docetaxel
(Taxotere, and others) for treatment of metastatic
non-small cell lung cancer that has progressed on or
after platinum-based...